KR910011810A - 옥사졸 유도체 - Google Patents
옥사졸 유도체 Download PDFInfo
- Publication number
- KR910011810A KR910011810A KR1019900021064A KR900021064A KR910011810A KR 910011810 A KR910011810 A KR 910011810A KR 1019900021064 A KR1019900021064 A KR 1019900021064A KR 900021064 A KR900021064 A KR 900021064A KR 910011810 A KR910011810 A KR 910011810A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- oxazolyl
- diphenyl
- methyl
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (49)
- 다음 일반식(Ⅰ)의 화합물상기 식중 n은 7-9이고 R은 수소 또는 저급알킬임.
- 제1항에 있어서, 메틸 4,5-데페닐-2-옥사졸노나노에이트인 화합물.
- 제1항에 있어서, 4,5-디페닐-2-옥사졸노난산인 화합물.
- 제1항에 있어서, 메틸4,5-디페닐-2-옥사졸옥타노에이트인 화합물.
- 제1항에 있어서, 4,5-디페닐-2-옥사졸옥탄산인 화합물.
- 다음 일반식(Ⅱ)의 화합물.상기 식중 R1은 페닐 또는 티에닐;R2는 수소, 저급알킬 이거나 또는 CO2와 함께 테트라졸-1-릴;X는CH2CH2, CH=CH, 및 CH2O 중에서 선택된 2가 결합기; Y는 OCH2, CH2CH2및 CH=CH중에서 선택되고 3또는 4페닐위치에 결합된 2가 결합기임.
- 제6항에 있어서, R1이 페닐인 화합물.
- 제6항에 있어서, R1이 페닐이고, X는 CH2CH2, Y는 OCH2인 화합물.
- 제6항에 있어서, 메틸2-[3-[2-(4,5-디페닐-2-옥사졸릴)에틸]페녹시]아세테이트인 화합물.
- 제6항에 있어서, 2-[3-[2-(디페닐-2-옥사졸릴)에틸]페녹시]초산인 화합물.
- 제10항 화합물의 나트륨염.
- 제6항에 있어서, 메틸2-[4-[2-(4,5-디페닐-2-옥사졸릴)에틸]페녹시]아세테이트인 화합물.
- 제6항에 있어서, 2-[4-[2-(4,5-디페닐-2-옥사졸릴)-에틸]페녹시]초산인 화합물.
- 제6항에 있어서, 에틸3-[3-[2-(4,5-디페닐-2-옥사졸릴)에틸]페닐]-에-프로페노에이트인 화합물.
- 제6항에 있어서, 3-[3-[2-(4,5-디페닐-2-옥사졸릴)에틸]페닐]-2-프로펜산 히드레이트 헥산 용매화합물인 화합물.
- 제6항에 있어서, 에틸3-[2-(4,5-디페닐-2-옥사졸릴)에틸]벤젠프로파노에티트인 화합물.
- 제6항에 있어서, 3-[2-(4,5-디페닐-2-옥사졸릴)에틸]벤젠프로판산인 화합물.
- 제6항에 있어서, 메틸[3-[2-(4,5-디페닐-2-옥사졸릴)에테닐]페녹옥]아세테이트인 화합물.
- 제6항에 있어서,[3-[2-(4,5-디페닐-2-옥사졸릴)에틸]페녹시]초산인 화합물.
- 제6항에 있어서, 메틸[4-[2-(4,5-디페닐-2-옥사졸릴)에테닐]페녹시]아세테이트인 화합물.
- 제6항에 있어서, 메틸[4-[2-(4,5-디페닐-2-옥사졸릴)에테닐]페녹시]초산인 화합물.
- 제6항에 있어서, 메틸3-[3-[(4,5-디페닐-2-옥사졸릴)메톡시]페닐]프로노에이트인 화합물.
- 제6항에 있어서, 3-[3-[2-(4,5-디페닐-2-옥사졸릴)-메톡시]페닐]프로판산인 화합물.
- 제6항에 있어서, 메틸3-[4-[(4,5-디페닐-2-옥사졸릴)메톡시]페닐]프로파노에이트인 화합물.
- 제6항에 있어서, 3-[4-[(4,5-디페닐-2-옥사졸릴)-메톡시]페닐]프로판산인 화합물.
- 제6항에 있어서, 메틸3-[3-[4,5-디페닐-2-옥사졸릴)메톡시]페닐]-2-프로페노에이트인 화합물.
- 제6항에 있어서, 3-[3-[(4,5-디페닐-2-옥사졸릴)메톡시]페닐]-2-프로펜산인 화합물.
- 제6항에 있어서, 메틸3-[4-[(4,5-디페닐-2-옥사졸릴)메톡시]페닐]-2-프로페노에이트인 화합물.
- 제6항에 있어서, 3-[4-(4,5-디페닐-2-옥사졸릴)-메톡시]페닐]-2-프로펜산인 화합물.
- 제6항에 있어서, 메틸[3-[(4,5-디페닐-2-옥사졸릴)메톡시]페녹시]아세테이트인 화합물.
- 제6항에 있어서, [3-[(4,5-디페닐-2-옥사졸릴)메톡시]페녹시]초산인 화합물.
- 제6항에 있어서, 에틸3-[3-[2-(4,5-디페닐-2-옥사졸릴)에틸]페닐]-2-프로페노에이트인 화합물.
- 제6항에 있어서,메틸[3-[2-(4,5-디(3-티에닐)-2-옥사졸릴)에틸]페녹시]아세테이트인 화합물.
- 제6항에 있어서, [3-[2-(4,5-디(3-티에닐)-2-옥사졸릴)에틸]페녹시]초산인 화합물.
- 제6항에 있어서, 메틸[3-[2-(4,5-디(2-티에닐)-2-옥사졸릴)에틸]페녹시]아세테이트인 화합물.
- 제6항에 있어서, [3-[2-(4,5-디(2-티에닐)-2-옥사졸릴)에틸]페녹시 초산인 화합물.
- 제6항에 있어서, 5-[[3-[2-(4,5-디페닐-2-옥사졸릴)-에틸]페녹시]메틸-1H-테트라졸릴 화합물.
- 제1항의 화합물의 치료적 유효량을 투여하는 것으로 됨을 특징으로 하는 비인간 포유류에 있어서의 혈소판응집 억제방법.
- 제1항의 화합물의 치료적 유효량과 약리적으로 혀용되는 담체로 이루어 짐을 특징으로 하는 혈소판응집 억제용 조성물.
- 제6항의 화합물 치료적 유효량을 투여하는 것으로 됨을 특징으로 하는 비인간 포유류에 있어서의 혈소판응집 억제방법.
- 제6항의 화합물의 치료적 유효량과 약리적으로 허용되는 담체로 이루어짐을 특징으로 하는 혈소판응집 억제용 조성물.
- 다음 일반식(ⅩⅨ)의 화합물.상기 식중 n은 7-9이고, R은 수소 또는 저급알킬임.
- 제42항에 있어서, 메틸8-[(4,5-디페닐-2-옥사졸릴)티오]옥타노에이트인 화합물.
- 제42항에 있어서, 8-[4,5-디페닐-2-옥사졸릴)티오]옥탄산인 화합물.
- 제42항의 화합물의 치료적 유효량과 약리적으로 허용되는 담체로 이루어짐을 특징으로하는 혈소판응집 억제용 조성물.
- 다음 일반식(ⅩⅩ)의 화합물.상기 식중 OCH6CO2R 부분이 3 또는 4 페널위치에서 부착되어 있고 R은 수소 또는 저급알킬임.
- 제46항에 있어서, 메틸[3-[[(4,5-디페닐-2-옥사졸릴)티오]메틸]페녹시]아세테이트인 화합물.
- 제46항에 있어서, [3-[[(4,5-디페닐-2-옥사졸릴)티오]메틸]페녹시]초산인 화합물.
- 제46항의 화합물의 치료적 유효량과 약리적으로 허용되는 담체로 이루어짐을 특징으로 하는 혈소판응집 억제용 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45354889A | 1989-12-20 | 1989-12-20 | |
US453,548 | 1989-12-20 | ||
US58002190A | 1990-09-10 | 1990-09-10 | |
US580021 | 1990-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR910011810A true KR910011810A (ko) | 1991-08-07 |
Family
ID=27037150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900021064A KR910011810A (ko) | 1989-12-20 | 1990-12-19 | 옥사졸 유도체 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0434034A1 (ko) |
JP (1) | JPH04217966A (ko) |
KR (1) | KR910011810A (ko) |
CN (4) | CN1028173C (ko) |
CA (1) | CA2032674A1 (ko) |
FI (1) | FI906213A (ko) |
HU (2) | HU206100B (ko) |
IL (1) | IL96747A0 (ko) |
NO (1) | NO905444L (ko) |
NZ (1) | NZ236474A (ko) |
PT (1) | PT96276A (ko) |
YU (1) | YU240990A (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5254576A (en) * | 1992-04-03 | 1993-10-19 | Bristol-Myers Squibb Company | Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors |
US5348969A (en) * | 1992-04-03 | 1994-09-20 | Bristol-Myers Squibb Company | Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors |
US5187188A (en) * | 1992-04-03 | 1993-02-16 | Bristol-Myers Squibb Company | Oxazole carboxylic acid derivatives |
US5362879A (en) * | 1993-04-15 | 1994-11-08 | Bristol-Myers Squibb Company | 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation |
DE4330959A1 (de) * | 1993-09-09 | 1995-03-16 | Schering Ag | Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
RU2176640C2 (ru) * | 1993-12-20 | 2001-12-10 | Фудзисава Фармасьютикал Ко., Лтд. | Гетероциклические соединения или их фармацевтически приемлемая соль, промежуточные соединения |
TW401408B (en) * | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
EP1067109B1 (en) * | 1998-03-10 | 2009-12-09 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
PE20060362A1 (es) * | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de oxazol como moduladores de ppar |
KR20080056288A (ko) * | 2005-11-07 | 2008-06-20 | 아이알엠 엘엘씨 | Ppar 조절제로서의 화합물 및 조성물 |
EP2816023A4 (en) | 2012-02-13 | 2015-09-09 | Takeda Pharmaceutical | AROMATIC CORE COMPOUND |
JP6121339B2 (ja) | 2012-02-13 | 2017-04-26 | 武田薬品工業株式会社 | 芳香環化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1206403A (en) * | 1966-12-15 | 1970-09-23 | Wyeth John & Brother Ltd | Oxazoles |
US3578671A (en) * | 1967-11-06 | 1971-05-11 | Wyeth John & Brother Ltd | Oxazoles |
DE2129012A1 (de) * | 1971-06-11 | 1973-01-04 | Merck Patent Gmbh | Azol-derivate |
US3895115A (en) * | 1974-03-01 | 1975-07-15 | Serono Ist Farm | Method of inhibiting platelet aggregation |
GB1507032A (en) * | 1974-08-06 | 1978-04-12 | Serono Lab | 2-thiol-4,5-diphenyloxazole s-derivatives |
-
1990
- 1990-12-14 NZ NZ236474A patent/NZ236474A/xx unknown
- 1990-12-17 FI FI906213A patent/FI906213A/fi not_active Application Discontinuation
- 1990-12-18 NO NO90905444A patent/NO905444L/no unknown
- 1990-12-19 CN CN90110135A patent/CN1028173C/zh not_active Expired - Fee Related
- 1990-12-19 CA CA002032674A patent/CA2032674A1/en not_active Abandoned
- 1990-12-19 KR KR1019900021064A patent/KR910011810A/ko not_active Application Discontinuation
- 1990-12-19 PT PT96276A patent/PT96276A/pt not_active Application Discontinuation
- 1990-12-19 EP EP90124776A patent/EP0434034A1/en not_active Ceased
- 1990-12-20 HU HU908361A patent/HU206100B/hu not_active IP Right Cessation
- 1990-12-20 JP JP2419324A patent/JPH04217966A/ja active Pending
- 1990-12-20 YU YU240990A patent/YU240990A/sh unknown
- 1990-12-20 IL IL96747A patent/IL96747A0/xx unknown
-
1992
- 1992-05-22 HU HU9201706A patent/HU9201706D0/hu unknown
-
1994
- 1994-04-12 CN CN94104206A patent/CN1101042A/zh active Pending
- 1994-04-12 CN CN94104210A patent/CN1101041A/zh active Pending
- 1994-04-12 CN CN94104211A patent/CN1101043A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
FI906213A (fi) | 1991-06-21 |
CN1101042A (zh) | 1995-04-05 |
NO905444L (no) | 1991-06-21 |
CA2032674A1 (en) | 1991-06-21 |
CN1101043A (zh) | 1995-04-05 |
HU908361D0 (en) | 1991-07-29 |
IL96747A0 (en) | 1991-09-16 |
YU240990A (sh) | 1992-12-21 |
NZ236474A (en) | 1993-07-27 |
CN1101041A (zh) | 1995-04-05 |
JPH04217966A (ja) | 1992-08-07 |
EP0434034A1 (en) | 1991-06-26 |
HUT59116A (en) | 1992-04-28 |
CN1028173C (zh) | 1995-04-12 |
CN1052667A (zh) | 1991-07-03 |
HU9201706D0 (en) | 1992-08-28 |
FI906213A0 (fi) | 1990-12-17 |
PT96276A (pt) | 1991-09-30 |
HU206100B (en) | 1992-08-28 |
NO905444D0 (no) | 1990-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910011810A (ko) | 옥사졸 유도체 | |
JPS5522636A (en) | Thiazoliding derivative | |
KR880007411A (ko) | 레티논산과 같은 작용을 갖는 에티닐헤테로 방향족-산류 | |
KR860004041A (ko) | 헤테로사이클릭 화합물의 제조방법 | |
KR830007685A (ko) | 세팔로스포린 유도체의 제조방법 | |
WO2003072100A1 (en) | Peroxisome proliferator activated receptor modulators | |
CA2098495A1 (en) | 1,4-benzothiazepine derivatives | |
KR870003991A (ko) | 치환된 벤젠 유도체의 제조방법 | |
KR840005425A (ko) | 1,4 디하이드로피리딘의 제조방법 | |
KR890005082A (ko) | 류코트리엔 ltd₄및 ltb₄길항제 | |
MA21028A1 (fr) | Nouveaux derives du IH,3H-pyrrolo (I,2-c) thiazole leur preparation et les compositions qui les contiennent | |
KR840006203A (ko) | N-포르밀 및 n-하이드록시메틸-3-펜옥시-1-아제티딘카복스아미드의 제조방법 | |
JPS6419016A (en) | Lipid control composition | |
KR910006302A (ko) | 세팔로스포린 유도체 | |
KR910011833A (ko) | 벤조[b]티오펜 유도체, 그의 제조방법 및 이를 함유하는 조성물 | |
EP0339671A3 (en) | Derivative of caffeic acid and pharmaceutical composition containing the same | |
EP0033617A3 (en) | Thiazolidine derivatives and their production and medicinal compositions containing them | |
KR900009657A (ko) | 세팔로스포린 화합물, 그 제조방법 및 용도 | |
KR840004757A (ko) | 세파로스포린 유도체의 제조방법 | |
KR840005126A (ko) | 디티오 화합물의 제조방법 | |
KR830007683A (ko) | 7β-[2-(2-아미노-4-티아졸릴)-2-(신)-메톡시 아미노 아세트 아미도]-3-세펨-4-카복실산의 에스테르의 제조방법 | |
KR890008087A (ko) | 알콕시 또는 벤질옥시기, 또는 벤질티오기로 치환된 디-t-부틸페놀 | |
KR900004686A (ko) | 류코트리엔 길항질 에스테르 전약제 | |
RU2006106281A (ru) | Производные бензоксазепина | |
EP1207157B1 (en) | Substituted benzylthiazolidine-2,4-dione derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |